The fact that MALT1 deficiency reduces neuroinflammation in the brain might also be of interest in the context of therapeutic modulation of other neurological pathologies involving neuroinflammation such as Alzheimer's disease (50), Parkinson's disease (51), multiple sclerosis (52), stroke (53), and neuropsychiatric diseases such as depression, schizophrenia, and autism (54, 55). This evidence concerns the gene MALT1 and Alzheimer disease.